In a turbulent stock market, three Motley Fool contributors recommend investing in CRISPR Therapeutics, Summit Therapeutics, and Viking Therapeutics, which they believe could see significant gains by 2030. CRISPR Therapeutics, despite recent struggles, has a promising gene-editing therapy, Casgevy, and a robust pipeline. Summit Therapeutics is poised to challenge established drugs with its ivonescimab, while Viking Therapeutics offers potential through its GLP-1 drug, VK2735, with ongoing clinical trials targeting obesity and metabolic disorders.
